Cancer Targeted Therapy Market & Clinical Insight 2015
Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles.
Small molecules cancer targeted therapeutics could be further divided into several categories depending upon cancer indications and target type. For instance, Gleevec by Novartis is tyrosine kinase inhibitor which is used in chronic myelogenous leukemia. Zelboraf by Roche is used for melanoma treatment which is a serine threonine kinase inhibitor. Multiple target inhibitors could also be observed in this segment which could be assigned to different cancer segments. Such capabilities allow them to erode profit margins of other drugs belonging to same and other cancer indications. It should also be noted that a single small molecule could fall in several segments due to which it could be used in lieu of similar drug. For instance, Lapatinib by GalaxoSmithKline acts on Her2/neu receptors and EGFR pathways related to breast cancer and lung cancer. Multiple target inhibitors contain both small and large molecule cancer targeted therapeutics. Various big pharmaceutical companies like Boehringer Ingelheim, Johnson & Johnson, Teva, Eli Lily and others are actively engaged in development of these molecules. Customizability of a molecule is among important factors that helps in increasing their market shares.
Large molecules like monoclonal antibodies are highly customizable due to which they could be formulated according to necessities of drug development program. Due to high versatility, they have been developed to target various molecules specific to particular cancer types. New target discovery could be considered as one of the most important factors affecting market growth of large molecule cancer targeted therapeutics. As compared to small molecule cancer targeted molecules, they have better pharmacological profiles and target binding efficacy due to which they would be able to occupy major market shares across the globe in coming years. They are still at emerging stages of industry life cycles due to which they offer significant marketing potential.
Clinical pipeline of innovative targeted therapeutics is increasing continuously due to which pharmaceutical companies would be able to generate more revenues. For instance, early diagnosis is a pre requisite of cancer patients undergoing cancer treatment. Paper carrying synthetic target molecule on surface is proposed to be used for identifying different cancers by soaking it in potential patient’s urine. Such tests are expected to be marketed in underdeveloped countries where early cancer diagnosis tests are costly. Other uses of nanotechnology is being discovered by investigators so that they could directly target specific molecules without affecting neighboring cells. Further, new biomarkers are at various phases of clinical trials that would be able to introduce new cancer targeted therapeutics in global market in coming years.
Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report:
- Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI
- Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors
- Cancer Vaccines Pipeline: 289 Cancer Vaccines
- Cancer Targeted Monoclonal Antibodies: 605 mAb
- Oncogene Inhibitors Pipeline: 185 oncogene inhibitors
- Introduction & Categorization of Cancer Targeted Therapies
- Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
- Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
- Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
- Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
- Global Cancer Targeted Therapeutics Market Dynamics
- Future Prospects of Cancer Targeted Therapies
2. NEED FOR CANCER TARGETED THERAPEUTICS
3. CATEGORIZATION OF CANCER TARGETED THERAPIES
4. CONSIDERATION OF CANCER VACCINES AS TARGETED THERAPEUTICS
5. MECHANISM OF CANCER VACCINES
5.1 Idiotype Cancer Vaccine Mechanism
5.2 Cellular Cancer Vaccines Mechanism
5.3 Ganglioside Antigens based Cancer Vaccines Mechanism
5.4 Peptide Cancer Vaccine Mechanism
5.5 Tumor Host Interaction Cancer Vaccine Mechanism
6. MECHANISMS OF CANCER TARGETED MONOCLONAL ANTIBODIES
6.1 Tumor Antigens as Targets of Antibodies
6.2 Development of Antibodies for Clinical Purposes
6.3 Complement Dependent Cytotoxicity (CDC)
6.4 Signal Transduction Changes
7. MECHANISM OF CANCER TARGETED TYROSINE KINASE THERAPEUTICS
8. MECHANISM OF ONCOGENE INHIBITORS
9. GLOBAL CANCER TARGETED THERAPY MARKET OVERVIEW
9.1 Current Market Scenario
9.2 Cancer Targeted Therapy Clinical Pipeline Insight
10. GLOBAL CANCER TARGETED THERAPEUTICS MARKET DYNAMICS
10.1 Favorable Market Parameters
10.2 Commercialization Challenges
11. FUTURE PROSPECTS OF CANCER TARGETED THERAPEUTICS
12. CANCER TARGETED MONOCLONAL ANTIBODIES PIPELINE BY COMPANY, INDICATION & PHASE
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase I
12.6 Phase I/II
12.7 Phase II
12.8 Phase II/III
12.9 Phase III
12.10 Preregistration
12.11 Registered
13. MARKETED CANCER MONOCLONAL ANTIBODIES BY INDICATION, COMPANY & COUNTRY
14. GLOBAL CANCER VACCINES CLINICAL PIPELINE INSIGHT BY COMPANY, INDICATION & PHASE
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered
15. MARKETED CANCER VACCINES CLINICAL INSIGHT BY INDICATION, COMPANY & COUNTRY
16. ONCOGENE INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE
16.1 Oncogene Protein Inhibitors Pipeline
16.2 Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline
16.3 Proto Oncogene Protein b raf Inhibitors Pipeline
16.4 Proto Oncogene Protein c-kit Inhibitors Pipeline
16.5 Proto-Oncogene Protein c-rel Inhibitors Pipeline
16.6 Proto Oncogene Protein c-akt Inhibitors Pipeline
16.7 Proto Oncogene Protein c met Inhibitors Pipeline
16.8 Proto Oncogene Protein c ret Inhibitors Pipeline
16.9 Proto-Oncogene Protein c mdm2 Inhibitors Pipeline
16.10 Proto-Oncogene Protein Inhibitors Pipeline
16.11 Proto-Oncogene-Protein-c-ets Inhibitors Pipeline
16.12 Proto-Oncogene Protein c-fli-1 Inhibitors Pipeline
16.13 Proto Oncogene Proteins c pim 1 Inhibitors Pipeline
16.14 Proto Oncogene Protein c-myc Inhibitors Pipeline
16.15 Multiple Oncogene Inhibitors Pipeline
17. MARKETED ONCOGENE INHIBITORS BY COMPANY & INDICATION
18. CANCER TARGETED TYROSINE KINASE CLINICAL TRIAL BY COMPANY, INDICATION & PHASE
18.1 Unknown
18.2 Research
18.3 Preclinical
18.4 Clinical
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-II/III
18.9 Phase-III
18.10 Preregistration
18.11 Registered
19. MARKETED CANCER TARGETED TYROSINE KINASE INHIBITORS
20. CANCER TARGETED ANGIOGENESIS INHIBITORS THERAPY PIPELINE BY COMPANY, PHASE & INDICATION
20.1 Unknown
20.2 Research
20.3 Preclinical
20.4 Clinical
20.5 Phase-I
20.6 Phase-I/II
20.7 Phase-II
20.8 Phase-III
21. MARKETED CANCER TARGETED ANGIOGENESIS INHIBITORS
22. COMPETITIVE LANDSCAPE
22.1 Advaxis
22.2 Bind Therapeutics
22.3 Boehringer Ingelheim
22.4 Bristol Mayer Squibb
22.5 Celldex Therapeutics
22.6 Dendreon Corporation
22.7 Eli Lily
22.8 GalaxoSmithKline
22.9 Galena Biopharma
22.10 Genetech
22.11 ImmunoCellular Therapeutics
22.12 ImmunoGen
22.13 Inovio Pharmaceuticals
22.14 Johnson & Johnson
22.15 NeoStem Oncology
22.16 NewLink Genetics
22.17 Northwest Biotherapeutics
22.18 Merck
22.19 Novartis
22.20 Peregrine Pharmaceuticals
22.21 Pfizer
22.22 Roche
22.23 Sanofi
22.24 Seattle Genetics
22.25 Teva
Figure 1-1: Uses of Pharmacogenomics
Figure 1-2: Developmental Stages of Targeted Therapeutics
Figure 1-3: Cancer Target Identification Techniques
Figure 1-4: Genetic Anomalies Classification
Figure 1-5: Mechanism of Cancer Targeted Therapeutics
Figure 1-6:Improvements Required for Cancer Targeted Therapies
Figure 2-1: Objectives of Cancer Targeted Therapeutics
Figure 2-2: Benefits of Cancer Targeted Therapeutics
Figure 3-1: Categorization of Cancer Targeted Therapeutics on the Basis of Molecular Size
Figure 3-2: Features of Cancer Targeted Small Molecules Drugs
Figure 3-3: Features of Cancer Targeting Antibodies
Figure 3-4: Classification of Cancer Targeted Therapies on the Basis of their Mechanism
Figure 4-1: Classification of Cancer Vaccines
Figure 4 2: Distinction of Cancer Vaccines
Figure 5-1: Classification of Different Types of Cancer vaccines
Figure 7-1: Benefits of Cancer Tyrosine Kinase Targeted Therapeutics
Figure 7-2: Classification of Tyrosine Kinase
Figure 7-3: Mechanism of Cancer Tyrosine Kinase Targeted Therapeutics
Figure 7-4: Mechanism of VEGFR
Figure 8-1: Activation of Proto-Oncogenes to Oncogenes
Figure 8-2:Benefits of Oncogene Inhibitors
Figure 8-3: Mechanism of Crizotinib
Figure 8-4: Mechanism of Vemurafenib
Figure 8-5: Mechanism of Vorinostat
Figure 9-1: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (%), 2015
Figure 9-2: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (Number), 2015
Figure 9-3: Global Cancer Vaccines Clinical Pipeline by Phase (%), 2015
Figure 9-4: Global Cancer Vaccines Clinical Pipeline by Phase (Number), 2015
Figure 9-5: Cancer Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
Figure 9-6: Cancer Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
Figure 9-7: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
Figure 9-8: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
Figure 9-9: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(%), 2015
Figure 9-10: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(Number), 2015
Figure 9-11: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
Figure 9-12: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
Figure 9-13: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
Figure 9-14: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
Figure 9-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
Figure 9-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
Figure 9-17: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(%), 2015
Figure 9-18: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(Number), 2015
Figure 9-19: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
Figure 9-20: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
Figure 9-21: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(%), 2015
Figure 9-22: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(Number), 2015
Figure 9-23: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(%), 2015
Figure 9-24: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(Number), 2015
Figure 9-25: Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
Figure 9-26: Multiple Oncogene Inhibitors Pipeline by Phase(number), 2015
Figure 9-27: Angienesis Inhibitors Pipeline by Phase (%), 2015
Figure 9-28: Angienesis Inhibitors Pipeline by Phase (Number), 2015
Figure 22-1: Advaxis Clinical Pipeline
Figure 22-2: Celldex Therapeutics Clinical Pipeline
Figure 22-3: Galena Biopharma Clinical Pipeline
Figure 22-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 22-5: ImmunoGen Clinical Pipeline
Figure 22-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 22-7: NewLink Genetics Corporation Clinical Pipeline
Figure 22-8: Northwest Biotherapeutics Clinical Pipeline
Figure 22-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 22-10: Seattle Genetics Clinical Pipeline
Cancer is a disease in which normal cells divide uncontrollably due to genetic alterations, while their heterogeneous genetic background makes it difficult to check their progression and proliferation. It can practically affect every organ in the body and cancerous cells can also spread to normal organs with the help of process called metastasis. In this way, secondary cancers are formed which further deteriorates the medical condition of cancer patients. Moreover, different pathophysiology of cancerous cells makes it difficult to develop suitable drugs that can offer long-term regression and effectively prevent cancer relapse.
Conventional cancer treatments like chemotherapy has played an important role in saving numerous lives but its modest therapeutic efficacy, severe side effects and high morbidity has created aversion among cancer patients. As a result, investigators are looking towards innovative solutions like cancer targeted therapeutics which can offer higher survival rates, high quality of live, better safety and efficacy profiles. However, cancer is quite complex to treat and lots of research is required to come forth with innovative cancer targeted therapeutics.
Furthermore, escalating cancer incidences has created a burgeoning pressure on investigators to come forth with effective cancer targeted therapeutics. Owing to these facts, pharmaceutical companies are investigating different fields for developing innovative cancer targeted therapeutics. In this regards, field of pharmacogenomics has allured them because it deals with the therapeutic efficacy of drugs in different genetic background. It helps in deciphering genes and associated pathways which could be used for developing cancer targeted therapeutics with high safety and efficacy profiles. Investigators are utilizing knowledge of pharmacogenomics for developing novel products that would have both pharmacological and commercialization potential.
As a result, pharmaceutical companies are investing more in research and development segment to come forth with innovative cancer targeted therapeutics. In coming years, several methodologies are expected to be developed that would be able to help pharmaceutical companies to generate more revenues.
Several decades of research done by investigators has resulted in identification of the actual reason behind neoplasm formation. Investigators have found that alteration of certain genes due to external or internal factors could be attributed to increased risk.
In certain pathways a single gene has been found to be responsible for development of cancer and this phenomenon is called oncogene addiction. Moreover, cancerous cells over express particular type of receptors which is not found in normal cells. This knowledge is used to develop targeted therapeutics that shows preferential interference with selective molecules related to check cancer. In past few years, therapeutics based on these molecular targets have been successfully developed and commercialized across the globe. It is expected that investigators would be able to identify new molecular targets having superior therapeutic efficacy.
Target identification is among one of the most essential steps on which future of drug development program is dependent. They are basis of rational drug design due to which it becomes more important to do it correctly for their therapeutic and commercial success. In 2003, Human Genome Project (HGP) to decipher human genetic makeup was completed and it gave several insights to choose correct target. Large human genome size and myriad of genes is among limiting factors which puzzles the investigators while searching for suitable targets. Most suitable gene sequences are chosen, structure is identified to develop counteracting target molecules followed by pre-clinical/clinical trials. This process seems simple but realistic technological challenges should be kept in mind which consumes significant time. Now, investigators have better tools, understanding of basic principles and many new findings are expected to take place in coming years. These measures are expected to help in commercialization of better targeted cancer therapeutics with higher safety and efficacy levels.
